Evaluation of the clinical utility of measuring serum infliximab and vedolizumab concentrations during monitoring of biologic therapy in patients with inflammatory bowel disease

Beata Kotowicz; Magdalena Chojnacka; Małgorzata Fuksiewicz; Piotr Kucha; Edyta Zagórowicz

doi:10.5114/pg.2025.147747

Streszczenie

3/2025 vol. 20

Artykuł oryginalny

Evaluation of the clinical utility of measuring serum infliximab and vedolizumab concentrations during monitoring of biologic therapy in patients with inflammatory bowel disease

Beata Kotowicz ¹

,

Magdalena Chojnacka ¹

,

Małgorzata Fuksiewicz ¹

,

Piotr Kucha ²

,

Edyta Zagórowicz ³

Cancer Biomarker and Cytokines Laboratory Unit, The Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Poland
Department of Gastroenterology, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Department of Gastroenterology, Hepatology, and Clinical Oncology, Center of Postgraduate Medical Education, Warsaw, Poland

Gastroenterology Rev 2025; 20 (3): 311–317

DOI: https://doi.org/10.5114/pg.2025.147747

Data publikacji online: 2025/01/31

Pełna treść artykułu

AMA

Kotowicz B, Chojnacka M, Fuksiewicz M, Kucha P, Zagórowicz E. Evaluation of the clinical utility of measuring serum infliximab and vedolizumab concentrations during monitoring of biologic therapy in patients with inflammatory bowel disease. Gastroenterology Review/Przegląd Gastroenterologiczny. 2025;20(3):311-317. doi:10.5114/pg.2025.147747.

APA

Kotowicz, B., Chojnacka, M., Fuksiewicz, M., Kucha, P., & Zagórowicz, E. (2025). Evaluation of the clinical utility of measuring serum infliximab and vedolizumab concentrations during monitoring of biologic therapy in patients with inflammatory bowel disease. Gastroenterology Review/Przegląd Gastroenterologiczny, 20(3), 311-317. https://doi.org/10.5114/pg.2025.147747

Chicago

Kotowicz, Beata, Magdalena Chojnacka, Małgorzata Fuksiewicz, Piotr Kucha, and Edyta Zagórowicz. 2025. "Evaluation of the clinical utility of measuring serum infliximab and vedolizumab concentrations during monitoring of biologic therapy in patients with inflammatory bowel disease". Gastroenterology Review/Przegląd Gastroenterologiczny 20 (3): 311-317. doi:10.5114/pg.2025.147747.

Harvard

Kotowicz, B., Chojnacka, M., Fuksiewicz, M., Kucha, P., and Zagórowicz, E. (2025). Evaluation of the clinical utility of measuring serum infliximab and vedolizumab concentrations during monitoring of biologic therapy in patients with inflammatory bowel disease. Gastroenterology Review/Przegląd Gastroenterologiczny, 20(3), pp.311-317. https://doi.org/10.5114/pg.2025.147747

MLA

Kotowicz, Beata et al. "Evaluation of the clinical utility of measuring serum infliximab and vedolizumab concentrations during monitoring of biologic therapy in patients with inflammatory bowel disease." Gastroenterology Review/Przegląd Gastroenterologiczny, vol. 20, no. 3, 2025, pp. 311-317. doi:10.5114/pg.2025.147747.

Vancouver

Kotowicz B, Chojnacka M, Fuksiewicz M, Kucha P, Zagórowicz E. Evaluation of the clinical utility of measuring serum infliximab and vedolizumab concentrations during monitoring of biologic therapy in patients with inflammatory bowel disease. Gastroenterology Review/Przegląd Gastroenterologiczny. 2025;20(3):311-317. doi:10.5114/pg.2025.147747.

Streszczenie

Evaluation of the clinical utility of measuring serum infliximab and vedolizumab concentrations during monitoring of biologic therapy in patients with inflammatory bowel disease

Udostępnij

Dostępne w

Indeksowane w

Zintergrowane z

Zasady redakcyjne